Tag: egrifta tesamorelin acetate market analysis

Discover trends, market shifts, and competitive outlooks for the egrifta (tesamorelin acetate) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Egrifta (Tesamorelin Acetate) Market Through 2034?#_x000D_

In recent times, the market size for egrifta (tesamorelin acetate) has experienced an XX (HCAGR). It’s projected that the market will expand from $XX million in 2024 to $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. Several factors can account for the growth during the historical period: heightened understanding of HIV-related complications, an upsurge in the need for drug therapy, heightened application of antiretroviral therapy, heightened focus on quality of life, medical research advancements, and increased awareness._x000D_

_x000D_

Anticipations are for the egrifta (tesamorelin acetate) market to witness a XX (FCAGR) rise in the upcoming few years. By 2029, the market is projected to expand to $XX million, signifying a compound annual growth rate (CAGR) of XX%. Numerous factors can be credited for this anticipated growth, some of which include the escalating chronicle ailments prevalence, an elevated number of hospitals, the surge in demand for sophisticated body health monitoring tools, a rise in metabolic disorder cases, and an increase in disease treatment awareness. The forecast period is also likely to see significant trends such as an increase in targeted treatment adoption, assimilation into inclusive care plans, the progression of personalized medicine, improved patient support programs, and an escalation in research activities._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Egrifta (Tesamorelin Acetate) Industry?#_x000D_

The escalating number of human immunodeficiency virus (HIV) instances is markedly propelling the expansion of the egrifta (tesamorelin acetate) market in the forthcoming years. Cases of HIV denote scenarios when individuals become infected with the virus, progressively undermining their immune system. The surge in HIV cases is partially attributed to a lack of adequate awareness and knowledge regarding preventive strategies, including using condoms and undergoing regular testing, especially among populations at high risk. Egrifta triggers the release of growth hormones that aid in reducing surplus visceral fat and enhancing body composition, hence considerably improving the overall health and quality of life for people living with HIV. For example, the Minnesota Department of Health, a health agency based in the U.S., reported in May 2024 that in 2023, there were 324 new HIV diagnoses, a 24% increase from 2022. Consequently, the rising prevalence of human immunodeficiency virus (HIV) instances is fueling the growth of the egrifta (tesamorelin acetate) market._x000D_

_x000D_

#How Is the Egrifta (Tesamorelin Acetate) Market Segmented?#_x000D_

The egrifta (tesamorelin acetate) market covered in this report is segmented –_x000D_

_x000D_

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels_x000D_

3) By End-Users: Hospitals, Specialized Clinics, Home Care_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20043&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Egrifta (Tesamorelin Acetate) Market Growth?#_x000D_

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Egrifta (Tesamorelin Acetate) Industry?#_x000D_

Focusing on the enhancement of treatment efficacy for HIV-related lipodystrophy through the development of advanced synthetic peptide drugs is a major trend in the egrifta (tesamorelin acetate) market. Synthetic peptide drugs, which are artificially created compounds, are designed to provide specific therapeutic benefits by either mimicking or improving the function of naturally occurring peptides. For example, in December 2024, Canada-based biopharmaceutical firm, Theratechnologies Inc., declared that the production of EGRIFTA SV has been restarted after voluntary closure of its contract manufacturer’s facility due to observations made during an FDA inspection. A freshly manufactured batch is ready for release upon receiving approval for a supplement, from the US Food and Drug Administration (FDA), and two more batches are currently in production. The firm is handling inventory to fulfill patient needs until mid-January 2025 and collaborates with the FDA to avoid a shortfall in 2025. EGRIFTA SV is exclusively distributed in the United States._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report_x000D_

_x000D_

#How Is the Egrifta (Tesamorelin Acetate) Market Defined and What Are Its Core Parameters?#_x000D_

Egrifta (tesamorelin acetate) is a synthetic peptide that reduces excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It acts as a growth hormone-releasing hormone (GHRH) analog to target and decrease visceral fat. By promoting fat breakdown, it improves fat distribution and reduces health risks associated with abdominal fat._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20043_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the egrifta (tesamorelin acetate) market grown in recent years?

In recent times, the egrifta (tesamorelin acetate) market has expanded by XX (HCAGR). The market size is projected to rise from $XX million in 2024 to $XX million in 2025, signifying a compound annual growth rate (CAGR) of XX%. This expansion during the historic period can be credited to the surge in understanding of HIV-related complications, escalating demand for medication therapy, increased application of antiretroviral therapy, heightened emphasis on quality of life, progress in medical research, and rising awareness.

How is the egrifta (tesamorelin acetate) market size expected to evolve during the forecast period?

Predictions suggest that the egrifta (tesamorelin acetate) market size will exhibit a CAGR of XX%, expanding to a valuation of $XX million by 2029. Several factors are contributing to this predicted growth over the forecasted period, including the increasing incidences of chronic diseases, the expansion in the number of hospitals, escalating demand for advanced health monitoring equipment, a rise in metabolic disorders’ occurrence and an increase in disease treatment awareness. The approaching period is also expected to see significant trends such as the growing use of precision treatments, integration with all-encompassing healthcare plans, the evolution of personalized medicine, the advancement in patient assistance programs, and an uptick in research endeavors.

Get your egrifta (tesamorelin acetate) market report here!

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which key drivers are propelling the egrifta (tesamorelin acetate) market’s growth?

The escalation of human immunodeficiency virus (HIV) incidences is providing substantial impetus to the growth of the egrifta (tesamorelin acetate) market in the coming years. The term HIV incidences denotes scenarios where people have contracted the HIV virus, causing their immune systems to deteriorate over time. Among the reasons for the spread of HIV are inadequate awareness and education regarding preventive methods, encompassing the usage of condoms and frequent screenings, notably within high-risk communities. Egrifta induces the secretion of the growth hormone, lowering excess internal fat and enhancing body composition. This, in turn, augments the overall health and quality of life in persons with HIV. For instance, the Minnesota Department of Health, a health agency based in the US, reported 324 fresh HIV cases in 2023, reflecting a 24% increase from 2022 in May 2024. Therefore, the heightened prevalence of human immunodeficiency virus (HIV) incidences is fueling the growth of the egrifta (tesamorelin acetate) market.

What are the market segments in the egrifta (tesamorelin acetate) industry?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

Which leading companies are shaping the growth of the egrifta (tesamorelin acetate) market?

Major companies operating in the egrifta (tesamorelin acetate) market include Theratechnologies Inc.

What key trends are currently impacting the egrifta (tesamorelin acetate) market’s development?

The primary trend in the egrifta (tesamorelin acetate) market is the concentrated effort on the development of sophisticated synthetic peptide drugs to augment efficiency in HIV-related lipodystrophy treatments. Synthetic peptide medication is engineered substances aimed at delivering a targeted therapeutic impact by simulating or boosting the functions of naturally produced peptides. Take, for example, Theratechnologies Inc., a Canadian biopharmaceutical firm announced the recommencement of EGRIFTA SV’s production in December 2024, after a deliberate shutdown of its contract manufacturer’s factory in response to FDA inspection findings. A newly produced batch has concluded quality control, awaiting the US Food and Drug Administration’s approval for a supplementary prior approval, while an extra two batches are still within their production phase. The firm is handling inventory in preparation for patient needs by mid-January 2025 and collaborating with the FDA in planning to avert potential scarcity in 2025. EGRIFTA SV is currently only available in the United States.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20043

Which geographic areas are influencing the growth of the egrifta (tesamorelin acetate) market?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Parathyroid Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Follicle Stimulating Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Egrifta (Tesamorelin Acetate) Market Over the 2025–2034 Period?

In recent times, the market size of egrifta (tesamorelin acetate) has experienced a XX (CAGR). The market is expected to escalate from $XX million in 2024 to $XX million in 2025, recording a compound annual growth rate (CAGR) of XX%. The growth during the historical period is due to factors such as an increase in understanding about HIV-related issues, a surge in the demand for drug treatments, a rise in the application of antiretroviral therapy, a greater emphasis on life quality, advancements in medical investigations, and heightened public awareness.

The market size for egrifta (tesamorelin acetate) is projected to experience an XX (CAGR) in the ensuing years, escalating to $XX million by 2029 at a compound annual growth rate (CAGR) of XX%. This anticipated expansion during the prediction span is tied to increasing instances of chronic illnesses, expansions in the number of hospitals, growing demand for sophisticated body health screening tools, a higher incidence of metabolic ailments, and heightened consciousness regarding disease management. The prediction period is set to see notable trends such as the mushrooming preference for targeted therapies, assimilation with all-inclusive treatment agendas, escalation in personalized healthcare, amplified patient support initiatives, and a surge in research pursuits.

What Are the Primary Drivers Supporting the Growth of the Egrifta (Tesamorelin Acetate) Market?

The surge in the number of human immunodeficiency virus (HIV) instances is markedly propelling the growth of the egrifta (tesamorelin acetate) market. HIV cases involve situations in which people are infected with HIV, which slowly erodes their immune systems. The escalating number of HIV cases can be partially attributed to a lack of adequate knowledge and education regarding prevention strategies, such as using condoms and undergoing regular check-ups, especially among vulnerable groups. Egrifta, by stimulating the release of the growth hormone, helps to reduce excess deep-seated fat and enhances body composition, ultimately enhancing the overall wellness and life quality for HIV patients. For example, in May 2024, the Minnesota Department of Health, a state health agency in the US, reported 324 fresh HIV diagnoses in 2023, which is a 24% increase from 2022. Therefore, the ascendance of human immunodeficiency virus (HIV) instances is fuelling the expansion of the egrifta (tesamorelin acetate) market.

Explore Comprehensive Insights Into The Global Egrifta (Tesamorelin Acetate) Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

Who Are the Influential Players Fueling Innovation and Growth in the Egrifta (Tesamorelin Acetate) Market?

Major companies operating in the egrifta (tesamorelin acetate) market include Theratechnologies Inc.

What Impact Are Industry Trends Having on the Egrifta (Tesamorelin Acetate) Market’s Future Prospects?

A major trend in the egrifta (tesamorelin acetate) market is the increased focus on creating highly advanced synthetic peptide drugs to improve treatments for HIV-related lipodystrophy. These synthetic peptide drugs are intentionally engineered substances looking to deliver targeted treatment results, either by replicating or improving the functions of natural peptides. For example, Theratechnologies Inc., a Biopharmaceutical firm based in Canada, declared in December 2024 that production of EGRIFTA SV was up and running again after a self-imposed halt at its contract maker’s facility because of observations during an FDA inspection. A freshly produced batch has gone through quality control and awaits the clearance of a prior approval supplement from US Food and Drug Administration (FDA), plus two extra batches are being produced. To satisfy patient needs till mid-January 2025, the company is managing its inventory and coordinating with the FDA to avoid any shortage in supply in 2025. EGRIFTA SV is exclusively available in the US.

Secure Your Global Egrifta (Tesamorelin Acetate) Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

How Are the Key Segments of the Egrifta (Tesamorelin Acetate) Market Impacting Its Expansion and Revenue Streams?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

What Regions Are Leading the Growth Trajectory of the Egrifta (Tesamorelin Acetate) Market?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Do Experts Define the Scope of the Egrifta (Tesamorelin Acetate) Market?

Egrifta (tesamorelin acetate) is a synthetic peptide that reduces excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It acts as a growth hormone-releasing hormone (GHRH) analog to target and decrease visceral fat. By promoting fat breakdown, it improves fat distribution and reduces health risks associated with abdominal fat.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Parathyroid Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Follicle Stimulating Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: